热门资讯> 正文

Sana Biotechnology非GAAP每股收益为-0.39美元

2025-08-12 04:45

Sana Biotechnology press release (NASDAQ:SANA): Q2 Non-GAAP EPS of -$0.39.
Cash, cash equivalents, and marketable securities as of June 30, 2025 were $72.7 million compared to $152.5 million as of December 31, 2024. The decrease of $79.8 million was primarily driven by cash used in operations of $81.8 million.

More on Sana Biotechnology

Sana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still Intrigued
Sana: HIP-Modified Islet Cells To Possibly Change Scope Of Type 1 Diabetes Treatment
Sana Biotechnology drops 13% on $75M stock issuance, prices at $3.35
Seeking Alpha’s Quant Rating on Sana Biotechnology
Historical earnings data for Sana Biotechnology

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。